We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
ConocoPhillips
COP
$144B
| $5.21M | 0.03% |
58,008
-49,783
| -46% | -$4.48M |
|
|
VIGL
552
DELISTED
Vigil Neuroscience
VIGL
| $5.2M | 0.03% |
653,619
+400,820
| +159% | +$1.8M |
|
553
Colgate-Palmolive
CL
$73.8B
| $5.16M | 0.03% |
56,801
+10,440
| +23% | +$953K |
|
554
Brinker International
EAT
$9.36B
| $5.16M | 0.03% |
28,604
-53,811
| -65% | -$8.44M |
|
555
Yum! Brands
YUM
$40.3B
| $5.15M | 0.03% |
34,763
-3,527
| -9% | -$515K |
|
556
Marvell Technology
MRVL
$196B
| $5.09M | 0.03% |
65,772
-89,354
| -58% | -$5.58M |
|
557
Liquidia Corp
LQDA
$7.86B
| $4.99M | 0.03% |
400,160
+100,000
| +33% | +$1.48M |
|
558
SLB Ltd
SLB
$75.4B
| $4.97M | 0.03% |
147,126
+28,775
| +24% | +$998K |
|
559
Fastenal
FAST
$57B
| $4.94M | 0.03% |
+117,561
| New | +$4.77M |
|
560
Allogene Therapeutics
ALLO
$656M
| $4.93M | 0.03% |
4,360,608
| – | – |
|
561
BellRing Brands
BRBR
$1.48B
| $4.93M | 0.03% |
85,057
-55,156
| -39% | -$3.68M |
|
|
CMPS
562
Compass Pathways
CMPS
$1.59B
| $4.92M | 0.03% |
1,755,938
+1,082
| +0.1% | +$4.07K |
|
563
Keurig Dr Pepper
KDP
$42.3B
| $4.86M | 0.03% |
146,905
+46,035
| +46% | +$1.56M |
|
564
Target
TGT
$67.3B
| $4.85M | 0.03% |
49,147
+10,435
| +27% | +$1M |
|
565
Crown Castle
CCI
$33.9B
| $4.84M | 0.03% |
47,103
+40,675
| +633% | +$4.12M |
|
566
MSCI
MSCI
$41.5B
| $4.83M | 0.03% |
8,369
+1,784
| +27% | +$987K |
|
567
Mondelez International
MDLZ
$79.2B
| $4.83M | 0.03% |
71,555
-6,735
| -9% | -$449K |
|
568
Fair Isaac
FICO
$22.6B
| $4.81M | 0.03% |
2,633
+495
| +23% | +$929K |
|
|
OS
569
DELISTED
OneStream Inc
OS
| $4.8M | 0.03% |
169,643
+35,743
| +27% | +$890K |
|
570
HUB Group
HUBG
$2.92B
| $4.79M | 0.03% |
+143,256
| New | +$4.81M |
|
571
IDEAYA Biosciences
IDYA
$3.48B
| $4.76M | 0.03% |
226,390
-88,982
| -28% | -$1.71M |
|
572
Monster Beverage
MNST
$92.1B
| $4.76M | 0.03% |
75,957
+16,799
| +28% | +$1.03M |
|
573
Kroger
KR
$35.4B
| $4.75M | 0.03% |
66,264
+10,021
| +18% | +$692K |
|
574
Exelon
EXC
$47.2B
| $4.74M | 0.03% |
109,200
+24,275
| +29% | +$1.08M |
|
575
Verisk Analytics
VRSK
$25.1B
| $4.71M | 0.02% |
15,131
+3,200
| +27% | +$970K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.